Stay updated on Pegcetacoplan in C3 Glomerulopathy: Clinical Trial

Sign up to get notified when there's something new on the Pegcetacoplan in C3 Glomerulopathy: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pegcetacoplan in C3 Glomerulopathy: Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Added Mesangiocapillary glomerulonephritis, type II to the study's condition terms.
    Difference
    0.0%
    Check dated 2026-04-02T05:00:16.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Added Complement 3 glomerulopathy to the study’s conditions list and removed Non-immunoglobulin-mediated membranoproliferative glomerulonephritis from the list.
    Difference
    0.0%
    Check dated 2026-03-25T22:45:25.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and Revision: v3.4.3 was removed.
    Difference
    0.0%
    Check dated 2026-03-18T19:42:58.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T18:17:35.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Added Non-immunoglobulin-mediated membranoproliferative glomerulonephritis as a term and linked the Genetic and Rare Diseases Information Center as a resource. Removed a government funding status notice and the older revision note (v3.4.1).
    Difference
    0.3%
    Check dated 2026-02-11T09:28:25.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    Inclusion criteria were updated to require stable doses of medications affecting proteinuria for at least 12 weeks prior to baseline, replacing the previous 812-week requirement. A government funding notice was added to the page, along with a revision entry indicating v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T05:56:01.000Z thumbnail image

Stay in the know with updates to Pegcetacoplan in C3 Glomerulopathy: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pegcetacoplan in C3 Glomerulopathy: Clinical Trial page.